Compare XNCR & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNCR | NNNN |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2013 | 2025 |
| Metric | XNCR | NNNN |
|---|---|---|
| Price | $18.36 | $40.63 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $23.20 | N/A |
| AVG Volume (30 Days) | ★ 758.3K | 26.4K |
| Earning Date | 11-05-2025 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $150,132,000.00 | $8,185,146.00 |
| Revenue This Year | $22.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $721.40 |
| Revenue Growth | ★ 38.16 | 21.95 |
| 52 Week Low | $6.92 | $5.18 |
| 52 Week High | $27.24 | $55.65 |
| Indicator | XNCR | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 72.16 |
| Support Level | $15.69 | $21.13 |
| Resistance Level | $17.83 | $29.38 |
| Average True Range (ATR) | 1.01 | 4.59 |
| MACD | 0.10 | 1.85 |
| Stochastic Oscillator | 91.72 | 91.32 |
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.